Table 6. Multivariate logistic regression analysis of selected treatments associated with AKI development following adjustment with age.

Patients	Treatment	OR	95% CI	P value
Overall Patients
AKI Stage I	ACEI/ARBS	1.31	0.62–2.78	n.s.
	Furosemide	2.83	1.48–5.41	<0.01
	Dexamethasone	3.06	1.48–6.33	<0.01
AKI Stage II+III	ACEI/ARBS	0.27	0.10–0.73	<0.01
	Furosemide	4.83	2.51–9.26	<0.001
	Dexamethasone	2.76	1.32–5.79	<0.01
Non-AKI		Ref	Ref	Ref
Hypertensive
AKI Stage I	ACEI/ARBS	0.73	0.25–2.14	n.s.
	Furosemide	2.83	1.48–5.41	<0.01
	Dexamethasone	4.56	1.25–16.52	<0.01
AKI Stage II+III	ACEI/ARBS	0.19	0.05–0.19	<0.05
	Furosemide	7.98	2.58–24.73	<0.001
	Dexamethasone	2.76	1.32–5.79	<0.05
Non-AKI		Ref	Ref	Ref
Diabetic
AKI Stage I	ACEI/ARBS	0.81	0.29–2.28	n.s.
	Furosemide	4.06	1.55–10.63	<0.01
	Dexamethasone	2.09	0.71–6.14	n.s.
AKI Stage II+III	ACEI/ARBS	0.19	0.05–0.19	<0.01
	Furosemide	7.49	2.71–20.69	<0.001
	Dexamethasone	2.24	0.72–6.95	n.s.
Non-AKI		Ref	Ref	Ref